Jci_page_head_homepage_01 Jci_page_head_homepage_02
Eric B. Brandt, Richard T. Strait, Dan Hershko, Quan Wang, Emily E. Muntel, Troy A. Scribner, Nives Zimmermann, Fred D. Finkelman, Marc E. Rothenberg
Published in Volume 112, Issue 11
J Clin Invest. 2003; 112(11):1666–1677 doi:10.1172/JCI19785
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1

A murine model of allergen-induced diarrhea. (a) The time line illustrates that mice were sensitized with two OVA/alum intraperitoneal (i.p.) injections (vertical hatch mark) and subsequently treated with intragastric (i.g.) saline or OVA challenges every 2–3 days (vertical lines). (b) Diarrhea occurrence was assessed 15–45 minutes after intragastric challenges with either saline or increasing doses of OVA (2–50 mg in 250 μl of saline). (c) Diarrhea occurrence in BALB/c mice (n = 16) was compared with C57Bl/6 mice (n = 8) following ten intragastric OVA challenges (50 mg). (d) Representative photograph of the cecum and colon of BALB/c mice 60 minutes after ten intragastric saline or OVA challenges (upper and lower two samples, respectively). (e) Nonsensitized mice (n = 8) or OVA/alum–sensitized mice (n = 15) were treated with repeated doses of intragastric OVA (50 mg). Following five doses of OVA, sensitized mice were challenged with BSA (50 mg) as a control before resuming OVA challenges.